Evidence-based medicine rests on an institutional architecture that is deliberately slow, cumulative, and imperfect: randomized trials, systematic reviews, independent advisory bodies, peer-reviewed grant allocation, and the gradual incorporation of negative results into clinical guidelines. It is not a pure meritocracy of pure reason; it is a system of checks designed to constrain both commercial capture and political whim. Under Donald Trump’s presidencies, that architecture has been subjected to sustained pressure, most sharply in the second term after January 2025. The effects are measurable in disrupted clinical trials, rewritten public-health recommendations, staff attrition at the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA), and a resurgence of vaccine-preventable disease. The record is not one of wholesale abolition of science, but of selective interruption of the processes that convert data into reliable clinical practice.
In the first term (2017–2021), the pattern was already visible. Proposed budgets repeatedly targeted CDC programs for emerging and zoonotic diseases and public-health scientific services; staff reductions in global health security posts in China and elsewhere reduced capacity just as SARS-CoV-2 emerged. During the pandemic, political officials pressed the FDA toward emergency authorization of hydroxychloroquine on the basis of anecdotal and preliminary data; subsequent randomized trials and observational studies failed to demonstrate clinical benefit and showed harms in certain populations. Guidance documents were altered, scientists reported pressure, and advisory processes were strained. Congress largely blocked the deepest budget cuts, and NIH appropriations rose overall, yet the episode illustrated how readily the boundary between evidence generation and political preference could be blurred.
The second term has intensified these dynamics under Health and Human Services Secretary Robert F. Kennedy Jr. Kennedy has long questioned the safety of routine childhood vaccines and has promoted theories linking them to autism and other chronic conditions—claims that large epidemiological studies and systematic reviews have repeatedly failed to support. In 2025 he ordered changes to CDC website language stating that the assertion “vaccines do not cause autism” is “not an evidence-based claim,” citing gaps in research on the full infant schedule rather than the MMR vaccine alone. He dismissed the entire 17-member Advisory Committee on Immunization Practices (ACIP) and appointed replacements that included vaccine skeptics. The reconstituted committee and subsequent administrative actions revised recommendations: COVID-19 vaccination for healthy children and pregnant women was no longer routinely advised; the hepatitis B birth dose was restricted or reframed for infants of mothers testing negative; thimerosal was further emphasized as a concern despite its prior removal from most childhood vaccines and the absence of causal evidence linking it to autism. Court challenges followed. A federal judge in 2026 blocked certain schedule reductions and found the new ACIP membership deficient in required expertise; the administration responded by amending the committee’s charter to broaden eligibility and heighten focus on adverse-event research.
Parallel actions reached the research infrastructure itself. Reports compiled from grant databases and researcher surveys document the termination, suspension, or disruption of thousands of federal awards—figures cited in congressional materials exceed $16 billion in disrupted funding for biomedical work on cancer, Alzheimer’s, diabetes, and other conditions, with more than $1 billion remaining canceled after court-ordered restorations. A JAMA Internal Medicine analysis identified 383 NIH-funded clinical trials whose grants were terminated between late February and mid-August 2025; more than 74,000 enrolled participants were affected, including those in active treatment or follow-up phases. Infectious-disease trials were disproportionately hit. Additional cuts targeted mRNA platform contracts and research on vaccine hesitancy. Staff reductions and voluntary departures at NIH, CDC, FDA, and the Agency for Healthcare Research and Quality further thinned institutional memory and review capacity. Scientific advisory committees across HHS were terminated or overhauled in large numbers.
The administration has framed these moves as restoration of “gold standard science.” Executive Order 14303 (May 2025) enumerates principles—reproducibility, transparency, falsifiability, unbiased peer review, acknowledgment of uncertainty, freedom from conflicts of interest—and directs agencies to align with them. Subsequent Office of Management and Budget proposals would give political appointees greater final authority over grant awards, potentially overriding traditional peer-review rankings when projects are judged misaligned with administration priorities. Critics, including scientific societies and journal editorials, argue that the language functions less as a methodological safeguard than as a warrant for political second-guessing of scientific judgment. The tension is structural: evidence-based medicine depends on relative insulation of evidentiary processes from immediate electoral incentives; democratic oversight properly includes budget and priority-setting, but not the retroactive rewriting of methodological norms.
Observable public-health consequences have followed. Measles, declared eliminated in the United States in 2000, produced 2,289 confirmed cases in 2025—the highest annual total in more than three decades—and by mid-to-late July 2026 had already surpassed that figure, with more than 2,300–2,400 cases reported across dozens of jurisdictions, the large majority in unvaccinated or under-vaccinated individuals. Outbreaks in under-vaccinated communities drove the numbers; kindergarten MMR coverage has fallen below the 95 percent threshold required for reliable herd protection in many areas. Experts have linked the trend, in part, to eroded confidence in vaccination recommendations. Hospitalizations and deaths remain far below historical epidemic levels, yet the loss of elimination status is now under active review.
None of this requires conspiracy or unique malevolence. Political administrations of every stripe have sought to shape research agendas; industry influence at the FDA has long been a legitimate concern; public trust in institutions eroded during and after the COVID-19 pandemic for reasons that include genuine scientific uncertainty, communication failures, and policy overreach. What distinguishes the present period is the scale of interruption to the intermediate institutions—advisory committees with domain expertise, continuous funding of multi-year trials, consistent evidentiary language on settled questions—that convert raw data into clinical guidance. When those institutions are dismantled or redirected faster than new evidence can accumulate, the result is not a purification of science but a transfer of authority from cumulative empirical processes to executive preference.
Evidence-based medicine is not self-executing. It requires material support, procedural continuity, and a shared commitment to update beliefs when data demand it. The record of the Trump administrations, particularly after 2025, shows repeated stress on each of those requirements in the domain of medicine. The long-term cost will be measured not only in canceled grants and rewritten schedules, but in the gradual thinning of the evidentiary chain on which clinical decisions depend.
